Venaxis, Inc. announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.18 USD | -4.13% |
|
+31.93% | -21.88% |
04:18pm | Stocks to watch as Biden, Trump vie for presidency | RE |
07:00am | Investors ride the 'Trump trade' as expectations grow for a second term | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.88% | 3.67B | |
+5.68% | 7.29B | |
+69.08% | 4.6B | |
-23.66% | 2.8B | |
+144.38% | 2.13B | |
+48.20% | 1.89B | |
+5.07% | 1.54B | |
+3.38% | 1.21B | |
-8.90% | 998M | |
-55.64% | 810M |
- Stock Market
- Equities
- RIOT Stock
- News Riot Platforms, Inc.
- Venaxis, Inc. Completes Patient Enrollment in Pivotal Clinical Trial of APPY1 Test